Global Monkeypox Treatment Market Insights Forecasts to 2033

• The Global Monkeypox treatment Market Size was Valued at USD 73 Million in 2023
• The Market Size is Growing at a CAGR of 11.20% from 2023 to 2033
• The Worldwide Monkeypox treatment Market Size is Expected to Reach USD 211 Million by 2033
• North America is Expected to Grow the fastest during the forecast period.

The Global Monkeypox Treatment Market Size is Anticipated to Exceed USD 211 Million by 2033, Growing at a CAGR of 11.20% from 2023 to 2033.

Market Overview

Monkeypox is a rare viral zoonotic disease caused by a double-stranded DNA virus belonging to the Orthopoxvirus genus of the Poxviridae family. It was first discovered in 1958 and has since spread to other central and western African countries. Two known clades of the virus are clade I and clade II. The first human case was recorded in the Democratic Republic of the Congo in 1970. Transmission between animals and humans occurs through direct contact with infected blood, bodily fluids, lesions, or fomites. Person-to-person transmission mostly occurs through close contact with respiratory droplets, skin lesions, infected fomites, and mother-to-child transmission via the placenta or at birth. Symptoms include fever, rash, and swollen lymph nodes. Monkeypox is usually mild and most people recover within a few weeks. Diagnostic testing involves real-time or conventional polymerase chain reaction. Vaccines developed to protect against smallpox and monkeypox may be used to prevent and treat monkeypox virus infections and antivirals. As per the data provided by the World Health Organization (WHO), from Jan 2022 and Aug 2024, over 120 countries reported mpox cases, with over 100,000 confirmed cases and over 220 deaths.

Report Coverage

This research report categorizes the market for the global monkeypox treatment market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global monkeypox treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global monkeypox treatment market.

Driving Factors

The monkeypox treatment market is driven by rising incidences of the disease globally, increased awareness of the disease's public health implications, and growing demand for rapid diagnostic solutions, effective vaccines, and antiviral treatments. Government initiatives, funding, and strategic collaborations between pharmaceutical companies and health organizations are accelerating research and development efforts. Also, the expanding healthcare infrastructure in emerging markets and increased regulatory approvals for vaccines and treatments like Tecovirimat (TPOXX) are fostering market growth.

Restraining Factors

The monkeypox treatment market faces challenges due to limited awareness, and high costs associated with vaccine development and distribution. The low prevalence of monkeypox as compared to other infectious diseases forces pharmaceutical companies to focus on large-scale research and development which decreases the innovation in the treatment of monkeypox. Also, the regulatory hurdles and lengthy approval processes further hinder market expansion.

Market Segmentation

The global monkeypox treatment market share is classified into route of administration, treatment, and end-user.

• The injectable segment is expected to hold the largest share of the global monkeypox treatment market during the forecast period.   

Based on the route of administration, the global monkeypox treatment market is divided into oral, injectable, and topical. Among these, the injectable segment is expected to hold the largest share of the global monkeypox treatment market during the forecast period. The injectable segment is anticipated to experience significant growth in the monkeypox treatment market due to the increasing use of injection-based vaccines like Jynneos and ACAM2000, as well as antiviral treatments like Tecovirimat via injections in severe cases. Governments and health organizations' focus on vaccination campaigns and advancements in delivery technologies are also driving demand for injectable treatments, contributing to the segment's expansion.

• The antiviral medication segment is expected to grow at the fastest CAGR in the global monkeypox treatment market during the forecast period.   

Based on the treatment, the global monkeypox treatment market is divided into antiviral medication, vaccines, supportive care, and immunoglobulins. Among these, the antiviral medication segment is expected to grow at the fastest CAGR in the global monkeypox treatment market during the forecast period. The antiviral medication segment is expected to experience significant growth in the monkeypox treatment market, due to the increasing use of antivirals like Tecovirimat (TPOXX). Governments and health agencies are accelerating approvals and stockpiling antiviral drugs to respond to the growing number of cases. Research into new and improved therapies supports the anticipated growth of this segment, highlighting the global concern over potential outbreaks and the demand for effective treatments.

• The hospital and clinics segment is expected to grow at the fastest CAGR in the global monkeypox treatment market during the forecast period.   

Based on the end-user, the global monkeypox treatment market is divided into hospitals and clinics, specialty centers, and research institutes. Among these, the hospitals and clinics segment is expected to grow at the fastest CAGR in the global monkeypox treatment market during the forecast period. The hospitals and clinics segment is expected to experience significant growth in the monkeypox treatment market due to their role as primary care centers for diagnosing and managing infectious diseases. With an increased influx of cases, demand for treatment and vaccines is driving the segment's growth. The focus on infectious disease preparedness and government funding for healthcare infrastructure strengthens the growth prospects of this segment.

Regional Segment Analysis of the Global Monkeypox Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global monkeypox treatment market over the predicted timeframe.

North America is anticipated to hold the largest share of the global monkeypox treatment market over the predicted timeframe. The region is expected to dominate the global monkeypox treatment market due to its advanced healthcare infrastructure, robust government outbreak control initiatives, and significant vaccine and antiviral therapies investments. The U.S. has led in stockpiling Jynneos and developing TPOXX, further strengthening its market position. Public health awareness and proactive disease prevention also contribute to its dominance.

Asia Pacific is expected to grow at the fastest pace in the global monkeypox treatment market during the forecast period. The region is expected to experience the fastest growth in the global monkeypox treatment market due to increasing awareness of infectious diseases, rising healthcare expenditures, and a focus on improving healthcare infrastructure in countries like China, Japan, and India. The region's large population and potential for zoonotic transmissions in densely populated and rural areas are driving governments and health organizations to prioritize vaccine development and distribution. Regional pharmaceutical companies' involvement in research and production also contributes to market expansion.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global monkeypox treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Emergent BioSolutions 
• Bavarian Nordic 
• SIGA Technologies 
• Chimerix 
• Pfizer Inc. 
• GlaxoSmithKline 
• Jinan Jinda Pharmaceutical Chemistry Co., Ltd
• Gilead Sciences 
• Merck & Co. 
• Moderna Inc. 
• Sanofi SA
• BioNTech 
• Emcure Pharmaceuticals
• Novartis 
• AstraZeneca 
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2022, Mayo Clinic Laboratories can now utilize the CDC's orthopoxvirus test kit to test for monkeypox, a rare viral infection.

• In June 2022, CerTest Biotec and Becton, Dickinson, and Company have partnered to create a molecular diagnostic test for the Monkeypox virus.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global Monkeypox treatment market based on the below-mentioned segments: 

Global Monkeypox Treatment Market, By Route of Administration

• Oral
• Injectable
• Topical

Global Monkeypox Treatment Market, By Treatment

• Antiviral Medication
• Vaccines
• Supportive Care
• Immunoglobulins

Global Monkeypox Treatment Market, By End-User

• Hospitals And Clinics
• Specialty Centers
• Research Institutes

Global Monkeypox Treatment Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa